Fu-Zai Yin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fu-Zai Yin has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
Chun-Ming Ma
Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, China
15 shared publicationsRui Wang
Department of Endocrinology , The First Hospital of Qinhuangdao , Qinhuangdao , Hebei Province , P.R. China
13 shared publicationsQiang Lu
Department of Endocrinology, The First Hospital of Qinhuangdao, Qinhuangdao, Hebei, China
12 shared publicationsNa Lu
Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of China
10 shared publicationsChunming Ma
Department of Endocrinology, The First Hospital of Qinhuangdao, Qinhuangdao, China
8 shared publicationsXiao-Li Liu
Department of Endocrinology, The First Hospital of Qinhuangdao, Qinhuangdao, China
7 shared publications
Latest Publications
- Open Access
- 1 May 2024
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 17, 2085-2094
Relationships Between the Apolipoprotein Levels and Sarcopenia in Inpatients with Type 2 Diabetes Mellitus: A Cross-Sectional Study
Background: Apolipoprotein (Apo) may be associated with sarcopenia in elderly inpatients with type 2 diabetes mellitus (T2DM), but fewer studies are available. In this study, we explored the association of ApoA1, ApoB, and ApoB/ApoA1 with sarcopenia and compared the predictive role of Apo indicators for sarcopenia in an elderly T2DM. Objective: To investigate the relationships between the Apo and sarcopenia in elderly inpatients with T2DM. Methods: This study included 253 inpatients with T2DM (mean age of 70.11± 5.44 years, 32.8% male). The inpatients were divided into the sarcopenic group (n = 100) and non-sarcopenic group (n = 153). The associations among the Apo and sarcopenia were assessed using multivariate analyses. Results: Inpatients in the sarcopenia group showed lower ApoA1 levels than those in the non-sarcopenia group (1.25± 0.21 vs 1.36± 0.20 g/L, P < 0.05) and showed higher ApoB/ApoA1 and ApoB levels than those in the non-sarcopenia group (0.82± 0.27 vs 0.69± 0.19 g/L, P < 0.05;1.00± 0.32 vs 0.93± 0.24 g/L, P < 0.05, respectively). After adjusting for age and BMI, the logistic regression model indicated that ApoA1 was a protective factor for elderly inpatients with T2DM sarcopenia.(OR =0.079,95% CI: 0.021~0.306, P < 0.05);ApoB and AopB/AopA1 were risk factors for elderly inpatients with T2DM sarcopenia.(OR =3.578,95% CI:1.318~9.715, P < 0.05;OR =16.440,95% CI:4.437~60.427, P < 0.05, respectively). AopB/AopA1 provided an AUC value of 0.765 in elderly men.(95% CI: 0.665~0.866, P< 0.05). Conclusion: ApoA1, AopB, and AopB/AopA1 are associated with sarcopenia in elderly inpatients with T2DM, and AopB/AopA1 may be a potential predictor of sarcopenia in elderly men with T2DM.
- 1 May 2024
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 17, 2085-2094
Open AccessRelationships Between the Apolipoprotein Levels and Sarcopenia in Inpatients with Type 2 Diabetes Mellitus: A Cross-Sectional Study
Background: Apolipoprotein (Apo) may be associated with sarcopenia in elderly inpatients with type 2 diabetes mellitus (T2DM), but fewer studies are available. In this study, we explored the association of ApoA1, ApoB, and ApoB/ApoA1 with sarcopenia and compared the predictive role of Apo indicators for sarcopenia in an elderly T2DM. Objective: To investigate the relationships between the Apo and sarcopenia in elderly inpatients with T2DM. Methods: This study included 253 inpatients with T2DM (mean age of 70.11± 5.44 years, 32.8% male). The inpatients were divided into the sarcopenic group (n = 100) and non-sarcopenic group (n = 153). The associations among the Apo and sarcopenia were assessed using multivariate analyses. Results: Inpatients in the sarcopenia group showed lower ApoA1 levels than those in the non-sarcopenia group (1.25± 0.21 vs 1.36± 0.20 g/L, P < 0.05) and showed higher ApoB/ApoA1 and ApoB levels than those in the non-sarcopenia group (0.82± 0.27 vs 0.69± 0.19 g/L, P < 0.05;1.00± 0.32 vs 0.93± 0.24 g/L, P < 0.05, respectively). After adjusting for age and BMI, the logistic regression model indicated that ApoA1 was a protective factor for elderly inpatients with T2DM sarcopenia.(OR =0.079,95% CI: 0.021~0.306, P < 0.05);ApoB and AopB/AopA1 were risk factors for elderly inpatients with T2DM sarcopenia.(OR =3.578,95% CI:1.318~9.715, P < 0.05;OR =16.440,95% CI:4.437~60.427, P < 0.05, respectively). AopB/AopA1 provided an AUC value of 0.765 in elderly men.(95% CI: 0.665~0.866, P< 0.05). Conclusion: ApoA1, AopB, and AopB/AopA1 are associated with sarcopenia in elderly inpatients with T2DM, and AopB/AopA1 may be a potential predictor of sarcopenia in elderly men with T2DM.
- Open Access
- 1 May 2023
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 16, 1505-1513
Relationship Between Hyperuricemia-Waist Phenotype and Obstructive Sleep Apnea in Type 2 Diabetes Mellitus
Objective: This study aimed to propose the hyperuricemia-waist (HUAW) phenotype and investigate the relationship between the HUAW phenotype and obstructive sleep apnea (OSA) in type 2 diabetes mellitus (T2DM). Methods: We enrolled 255 patients with T2DM (165 male and 90 female) from the First Hospital of Qinhuangdao. The sleep test was performed, and serum uric acid (UA) levels and waist circumference (WC) were calculated. The HUAW phenotype was defined as serum UA concentrations ≥ 420 μmol/L and WC ≥ 90 cm (male) and ≥ 85 cm (female). The participants were categorized into four phenotype groups based on the mentioned cutoffs: normal WC and normal UA concentrations (group A); normal WC and elevated UA concentrations (group B); enlarged WC and normal UA concentrations (group C); and enlarged WC and elevated UA concentrations (group D). Among these participants, 17.6% were characterized by the HUAW phenotype, 80.0% had OSA, and 47.0% had moderate-to-severe OSA. The prevalence of OSA was 43.4%, 71.4%, 89.7%, and 97.8% in groups A, B, C, and D, respectively. The prevalence of moderate-to-severe OSA was 7.5%, 28.6%, 56.9%, and 72.7% in groups A, B, C, and D, respectively. After adjusting for age, sex, duration of diabetes, glycosylated hemoglobin A1c, smoking, and drinking, the HUAW phenotype was found to be significantly associated with OSA and moderate-to-severe OSA. Conclusion: The present study proposed the HUAW phenotype and demonstrated that in T2DM, the HUAW phenotype was associated with OSA, especially with moderate-to-severe OSA. Unlike T2DM without the HUAW phenotype, T2DM with the HUAW phenotype showed a significantly higher prevalence of OSA, especially moderate-to-severe OSA. Thus, early sleep studies should be routinely examined in individuals with T2DM who display the HUAW phenotype.
- 1 May 2023
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 16, 1505-1513
Open AccessRelationship Between Hyperuricemia-Waist Phenotype and Obstructive Sleep Apnea in Type 2 Diabetes Mellitus
Objective: This study aimed to propose the hyperuricemia-waist (HUAW) phenotype and investigate the relationship between the HUAW phenotype and obstructive sleep apnea (OSA) in type 2 diabetes mellitus (T2DM). Methods: We enrolled 255 patients with T2DM (165 male and 90 female) from the First Hospital of Qinhuangdao. The sleep test was performed, and serum uric acid (UA) levels and waist circumference (WC) were calculated. The HUAW phenotype was defined as serum UA concentrations ≥ 420 μmol/L and WC ≥ 90 cm (male) and ≥ 85 cm (female). The participants were categorized into four phenotype groups based on the mentioned cutoffs: normal WC and normal UA concentrations (group A); normal WC and elevated UA concentrations (group B); enlarged WC and normal UA concentrations (group C); and enlarged WC and elevated UA concentrations (group D). Among these participants, 17.6% were characterized by the HUAW phenotype, 80.0% had OSA, and 47.0% had moderate-to-severe OSA. The prevalence of OSA was 43.4%, 71.4%, 89.7%, and 97.8% in groups A, B, C, and D, respectively. The prevalence of moderate-to-severe OSA was 7.5%, 28.6%, 56.9%, and 72.7% in groups A, B, C, and D, respectively. After adjusting for age, sex, duration of diabetes, glycosylated hemoglobin A1c, smoking, and drinking, the HUAW phenotype was found to be significantly associated with OSA and moderate-to-severe OSA. Conclusion: The present study proposed the HUAW phenotype and demonstrated that in T2DM, the HUAW phenotype was associated with OSA, especially with moderate-to-severe OSA. Unlike T2DM without the HUAW phenotype, T2DM with the HUAW phenotype showed a significantly higher prevalence of OSA, especially moderate-to-severe OSA. Thus, early sleep studies should be routinely examined in individuals with T2DM who display the HUAW phenotype.
- Open Access
- 30 March 2023
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (10) , 7629-7636
J-shaped association between uric acid and breast cancer risk: a prospective case–control study
Background/aim: In terms of breast cancer risk, there is no consensus on the effect of uric acid (UA) levels. The aim of our study was to clarify the link between UA and breast cancer risk in a prospective case–control study and to find the UA threshold point. Methods: We designed a case–control study with 1050 females (525 newly diagnosed breast cancer patients and 525 controls). We measured the UA levels at baseline and confirmed the incidence of breast cancer through postoperative pathology. We used binary logistic regression to study the association between breast cancer and UA. In addition, we performed restricted cubic splines to evaluate the potential nonlinear links between UA and breast cancer risk. We used threshold effect analysis to identify the UA cut-off point. Results: After adjusting for multiple confounding factors, we found that compared with the referential level (3.5–4.4 mg/dl), the odds ratio (OR) of breast cancer was 1.946 (95% CI 1.140–3.321) (P < 0.05) in the lowest UA level and 2.245 (95% CI 0.946–5.326) (P > 0.05) in the highest level. Using the restricted cubic bar diagram, we disclosed a J-shaped association between UA and breast cancer risk (P-nonlinear < 0.05) after adjusting for all confounders. In our study, 3.6 mg/dl was found to be the UA threshold which acted as the optimal turning point of the curve. The OR for breast cancer was 0.170 (95% CI 0.056–0.512) to the left and 1.283 (95% CI 1.074–1.532) to the right of 3.6 mg/dl UA (P for log likelihood ratio test < 0.05). Conclusion: We found a J-shaped association between UA and breast cancer risk. Controlling the UA level around the threshold point of 3.6 mg/dl provides a novel insight into breast cancer prevention.
- 30 March 2023
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (10) , 7629-7636
Open AccessJ-shaped association between uric acid and breast cancer risk: a prospective case–control study
Background/aim: In terms of breast cancer risk, there is no consensus on the effect of uric acid (UA) levels. The aim of our study was to clarify the link between UA and breast cancer risk in a prospective case–control study and to find the UA threshold point. Methods: We designed a case–control study with 1050 females (525 newly diagnosed breast cancer patients and 525 controls). We measured the UA levels at baseline and confirmed the incidence of breast cancer through postoperative pathology. We used binary logistic regression to study the association between breast cancer and UA. In addition, we performed restricted cubic splines to evaluate the potential nonlinear links between UA and breast cancer risk. We used threshold effect analysis to identify the UA cut-off point. Results: After adjusting for multiple confounding factors, we found that compared with the referential level (3.5–4.4 mg/dl), the odds ratio (OR) of breast cancer was 1.946 (95% CI 1.140–3.321) (P < 0.05) in the lowest UA level and 2.245 (95% CI 0.946–5.326) (P > 0.05) in the highest level. Using the restricted cubic bar diagram, we disclosed a J-shaped association between UA and breast cancer risk (P-nonlinear < 0.05) after adjusting for all confounders. In our study, 3.6 mg/dl was found to be the UA threshold which acted as the optimal turning point of the curve. The OR for breast cancer was 0.170 (95% CI 0.056–0.512) to the left and 1.283 (95% CI 1.074–1.532) to the right of 3.6 mg/dl UA (P for log likelihood ratio test < 0.05). Conclusion: We found a J-shaped association between UA and breast cancer risk. Controlling the UA level around the threshold point of 3.6 mg/dl provides a novel insight into breast cancer prevention.
- Open Access
- 13 March 2023
- Published by Springer Nature in Research Square
Association between plasma irisin and impaired glucose regulation among Chinese young men: a cross-sectional study
Objective: To investigate the association between plasma irisin and impaired glucose regulation (IGR) among Chinese young men. Materials and Methods: This cross-sectional study involved 86 Chinese male subjects, aged 18-45 years, who visited the First Hospital of Qinhuangdao (Hebei, China) in 2017 for annual health check-up. Anthropometric measurements, including height, weight and waist circumference (WC) were performed. All patients underwent an oral glucose tolerance test (OGTT) after 8 hours of fasting, and the levels of glucose, insulin, lipids and serum irisin were measured. Participants were categorized into: normal glucose tolerance (NGT) [fasting plasma glucose (FPG)<5.6 mmol/L, and 2-h plasma glucose (2hPG) <7.8 mmol/L after a 75-g OGTT]; IGR[impaired fasting glucose (IFG) ( 5.6mmol/l ≤FPG<7.0 mmol/L, and 2hPG<7.8 mmol/L ) and impaired glucose tolerance (IGT) (FPG<5.6 mmol/L, and 7.8 mmol/l ≤2hPG<11.1 mmol/L]. Results: Subjects in the IGR group had higher body mass index (BMI), WC, FPG, 2hPG and homeostasis model assessment of insulin resistance (HOMA-IR), and lower high-density lipoprotein cholesterol(HDL-C) than subjects in the NGT group (P < 0.05). The levels of serum irisin (4.43 ± 1.44 vs. 6.25 ± 1.46 µg/mL) were significantly lower in the IGR group (P<0.05). The prevalence of obesity (42.2% vs. 65.9%), abdominal obesity (66.7% vs. 85.4%), high levels of triglyceride(22.2% vs. 41.5%), low levels of HDL-C (8.9% vs. 41.5%) and low levels of irisin (26.7% vs. 75.6%) was significantly higher among cases in the IGR group (P <0.05). A multiple logistic regression showed that irisin (OR=0.110, P= 0.000) and HOMA-IR (OR=5.586, P = 0.011) were independent risk factors for predicting IGR. Conclusions: Serum irisin levels were reduced in Chinese young men with IGR. Reduced irisin may increase the occurrence of IGR. It suggested that irisin may predict the occurrence of impaired glucose homeostasis and should be examined in future studies.
- 13 March 2023
- Published by Springer Nature in Research Square
Open AccessAssociation between plasma irisin and impaired glucose regulation among Chinese young men: a cross-sectional study
Objective: To investigate the association between plasma irisin and impaired glucose regulation (IGR) among Chinese young men. Materials and Methods: This cross-sectional study involved 86 Chinese male subjects, aged 18-45 years, who visited the First Hospital of Qinhuangdao (Hebei, China) in 2017 for annual health check-up. Anthropometric measurements, including height, weight and waist circumference (WC) were performed. All patients underwent an oral glucose tolerance test (OGTT) after 8 hours of fasting, and the levels of glucose, insulin, lipids and serum irisin were measured. Participants were categorized into: normal glucose tolerance (NGT) [fasting plasma glucose (FPG)<5.6 mmol/L, and 2-h plasma glucose (2hPG) <7.8 mmol/L after a 75-g OGTT]; IGR[impaired fasting glucose (IFG) ( 5.6mmol/l ≤FPG<7.0 mmol/L, and 2hPG<7.8 mmol/L ) and impaired glucose tolerance (IGT) (FPG<5.6 mmol/L, and 7.8 mmol/l ≤2hPG<11.1 mmol/L]. Results: Subjects in the IGR group had higher body mass index (BMI), WC, FPG, 2hPG and homeostasis model assessment of insulin resistance (HOMA-IR), and lower high-density lipoprotein cholesterol(HDL-C) than subjects in the NGT group (P < 0.05). The levels of serum irisin (4.43 ± 1.44 vs. 6.25 ± 1.46 µg/mL) were significantly lower in the IGR group (P<0.05). The prevalence of obesity (42.2% vs. 65.9%), abdominal obesity (66.7% vs. 85.4%), high levels of triglyceride(22.2% vs. 41.5%), low levels of HDL-C (8.9% vs. 41.5%) and low levels of irisin (26.7% vs. 75.6%) was significantly higher among cases in the IGR group (P <0.05). A multiple logistic regression showed that irisin (OR=0.110, P= 0.000) and HOMA-IR (OR=5.586, P = 0.011) were independent risk factors for predicting IGR. Conclusions: Serum irisin levels were reduced in Chinese young men with IGR. Reduced irisin may increase the occurrence of IGR. It suggested that irisin may predict the occurrence of impaired glucose homeostasis and should be examined in future studies.
- Open Access
- 1 February 2023
- Published by Springer Nature in Research Square
LDL-C/HDL-C ratio:a strong metabolic risk factor of invasive breast cancer
Objective:Our study aims to evaluate whether low density lipoprotein cholesterol/high density lipoprotein cholesterol (LDL-C/HDL-C) can act as a metabolic risk factor of invasive breast cancer (BC) in females. Methods: From January,2022 to December, 2022,505 females invasive BC and 505 age-matched controls were prospectively enrolled in our study. Data were obtained via medical records and questionnaires.We used Student’s t-test and Pearson’s χ2 test to assess the baseline characterisitcs, and binary logistic regression was utilized to clarify the metabolic risk factors of invasive BC. Finally, stratified analyses were performed according to estrogen receptor(ER) status. Results: LDL-C/HDL-C,waist circumference (WC),coronary heart disease and family history of cancer were independent risk factors of invasive BC. Among the metabolic factors,higher LDL-C/HDL-C ratio(OR,25.19,95%CI,13.15-48.25) and WC(OR,1.20,95%CI,1.15-1.24) were associa- -ted with higher BC risk(PP<0.05). Conclusions: We find that LDL-C/HDL-C ratio is a strong metabolic risk factor of invasive BC regardless of whether ER status was positive or negative.
- 1 February 2023
- Published by Springer Nature in Research Square
Open AccessLDL-C/HDL-C ratio:a strong metabolic risk factor of invasive breast cancer
Objective:Our study aims to evaluate whether low density lipoprotein cholesterol/high density lipoprotein cholesterol (LDL-C/HDL-C) can act as a metabolic risk factor of invasive breast cancer (BC) in females. Methods: From January,2022 to December, 2022,505 females invasive BC and 505 age-matched controls were prospectively enrolled in our study. Data were obtained via medical records and questionnaires.We used Student’s t-test and Pearson’s χ2 test to assess the baseline characterisitcs, and binary logistic regression was utilized to clarify the metabolic risk factors of invasive BC. Finally, stratified analyses were performed according to estrogen receptor(ER) status. Results: LDL-C/HDL-C,waist circumference (WC),coronary heart disease and family history of cancer were independent risk factors of invasive BC. Among the metabolic factors,higher LDL-C/HDL-C ratio(OR,25.19,95%CI,13.15-48.25) and WC(OR,1.20,95%CI,1.15-1.24) were associa- -ted with higher BC risk(PP<0.05). Conclusions: We find that LDL-C/HDL-C ratio is a strong metabolic risk factor of invasive BC regardless of whether ER status was positive or negative.
- Open Access
- 1 November 2022
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 1035114
The dose-response relationship between sex hormones and hyperuricemia in different gender: NHANES 2013-2016
Objectives: To access the dose-response relationship between sex hormones and hyperuricemia (HUA), and to find the cut-off value in different gender.Methods: 9,685 participants were derived from the database of National Health and Nutrition Examination Survey (NHANES). Restricted cubic spline (RCS) analysis were applied to explore the relationship between sex hormones and HUA after adjusting for confounding factors by propensity score match (PSM). Logistic regression was used to estimate the odds ratio (OR) and 95% CI.Results: The prevalence of HUA was 15.13% in female participants and 22.30% in male participants. Logistic regression analysis showed that estradiol (E2) was independently associated with HUA for a P value of 0.003 and 0.01in female and male participants, respectively. Testosterone (T) was only independently associated with HUA in male participants (P<0.001) but not in female participants (P = 0.59). RCS analysis showed a dose-response relationship between sex hormones and HUA. The risk of HUA increased as E2 lower than 29.6pg/mL in female participants and T lower than 389.1ng/dL in male participants. E2 higher than 23.6pg/ml was an independent risk factor for HUA in male participants.Conclusion: A dose-response relationship was found between sex hormones and HUA. The cut-off value of E2 in male and female participants was 29.6pg/mL and 23.6pg/mL, respectively, and the cut-off value of T in male participants was 389.1ng/dL. These results provide a reference for preventing HUA and hormone supplement therapy.
- 1 November 2022
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 1035114
Open AccessThe dose-response relationship between sex hormones and hyperuricemia in different gender: NHANES 2013-2016
Objectives: To access the dose-response relationship between sex hormones and hyperuricemia (HUA), and to find the cut-off value in different gender.Methods: 9,685 participants were derived from the database of National Health and Nutrition Examination Survey (NHANES). Restricted cubic spline (RCS) analysis were applied to explore the relationship between sex hormones and HUA after adjusting for confounding factors by propensity score match (PSM). Logistic regression was used to estimate the odds ratio (OR) and 95% CI.Results: The prevalence of HUA was 15.13% in female participants and 22.30% in male participants. Logistic regression analysis showed that estradiol (E2) was independently associated with HUA for a P value of 0.003 and 0.01in female and male participants, respectively. Testosterone (T) was only independently associated with HUA in male participants (P<0.001) but not in female participants (P = 0.59). RCS analysis showed a dose-response relationship between sex hormones and HUA. The risk of HUA increased as E2 lower than 29.6pg/mL in female participants and T lower than 389.1ng/dL in male participants. E2 higher than 23.6pg/ml was an independent risk factor for HUA in male participants.Conclusion: A dose-response relationship was found between sex hormones and HUA. The cut-off value of E2 in male and female participants was 29.6pg/mL and 23.6pg/mL, respectively, and the cut-off value of T in male participants was 389.1ng/dL. These results provide a reference for preventing HUA and hormone supplement therapy.
- Open Access
- 24 October 2022
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 86 (2) , 166-175
Hypoglycemic drug liraglutide alleviates low muscle mass by inhibiting the expression of MuRF1 and MAFbx in diabetic muscle atrophy
Background: Low muscle mass, that is, muscular atrophy, is an independent risk factor for type 2 diabetes mellitus (T2DM). Few studies investigated whether hypoglycemic drugs can alleviate low muscle mass and related mechanisms. Methods: This study recruited 51 type 2 diabetes mellitus (T2DM) patients, who were divided into two groups based on skeletal muscle index (SMI) evaluated by Dual-energy X-ray absorptiometry (DXA): the experiment group (n = 25, SMI < 7 kg/m2) and the control group (n = 26, SMI≥7 kg/m2). GLP-1 levels were measured by ELISA. In vitro, 10 KK-Ay mice (11- to 12-week-old) were assigned into two groups: liraglutide group (n = 5) and saline group (n = 5). Real-time PCR and Western blot were used to determine the expression levels of muscle specific ubiquitin protease E3, MuRF1, and MAFbx. Results: T2DM patients with a higher SMI had significantly higher GLP-1 levels (t = 3.77, p < 0.001). SMI were positively associated with GLP-1 levels (β = 0.435, p = 0.001) and inversely associated with age (β = 0.299, p = 0.015). The incidence of low muscle mass at below the second quartiles was 10.55 times that of above the second quartiles (odds ratio = 10.556, p < 0.001). Liraglutide-treatment mice showed significant decrease in food intake, final body weight, fasting blood glucose, and significant increase in skeletal muscle mass, which coincided with the significant decrease in the expression levels of ubiquitin protease E3 MuRF1 and MAFbx. In vitro studies showed that liraglutide promoted myogenic differentiation and attenuated dexamethasone (DEX)-induced myotube atrophy. Ectopic expression of MuRF1 and MAFbx antagonized the beneficial effects of liraglutide on DEX-induced myotube atrophy. Conclusion: T2DM patients have muscular atrophy, and liraglutide alleviates muscular atrophy at least in part by inhibiting the expression of MuRF1 and MAFbx.
- 24 October 2022
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 86 (2) , 166-175
Open AccessHypoglycemic drug liraglutide alleviates low muscle mass by inhibiting the expression of MuRF1 and MAFbx in diabetic muscle atrophy
Background: Low muscle mass, that is, muscular atrophy, is an independent risk factor for type 2 diabetes mellitus (T2DM). Few studies investigated whether hypoglycemic drugs can alleviate low muscle mass and related mechanisms. Methods: This study recruited 51 type 2 diabetes mellitus (T2DM) patients, who were divided into two groups based on skeletal muscle index (SMI) evaluated by Dual-energy X-ray absorptiometry (DXA): the experiment group (n = 25, SMI < 7 kg/m2) and the control group (n = 26, SMI≥7 kg/m2). GLP-1 levels were measured by ELISA. In vitro, 10 KK-Ay mice (11- to 12-week-old) were assigned into two groups: liraglutide group (n = 5) and saline group (n = 5). Real-time PCR and Western blot were used to determine the expression levels of muscle specific ubiquitin protease E3, MuRF1, and MAFbx. Results: T2DM patients with a higher SMI had significantly higher GLP-1 levels (t = 3.77, p < 0.001). SMI were positively associated with GLP-1 levels (β = 0.435, p = 0.001) and inversely associated with age (β = 0.299, p = 0.015). The incidence of low muscle mass at below the second quartiles was 10.55 times that of above the second quartiles (odds ratio = 10.556, p < 0.001). Liraglutide-treatment mice showed significant decrease in food intake, final body weight, fasting blood glucose, and significant increase in skeletal muscle mass, which coincided with the significant decrease in the expression levels of ubiquitin protease E3 MuRF1 and MAFbx. In vitro studies showed that liraglutide promoted myogenic differentiation and attenuated dexamethasone (DEX)-induced myotube atrophy. Ectopic expression of MuRF1 and MAFbx antagonized the beneficial effects of liraglutide on DEX-induced myotube atrophy. Conclusion: T2DM patients have muscular atrophy, and liraglutide alleviates muscular atrophy at least in part by inhibiting the expression of MuRF1 and MAFbx.
- Open Access
- 1 June 2022
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 882977
Age, Pulse, Urea, and Albumin Score: A Tool for Predicting the Short-Term and Long-Term Outcomes of Community-Acquired Pneumonia Patients With Diabetes
Objective: The predictive performances of CURB-65 and pneumonia severity index (PSI) were poor in patients with diabetes. This study aimed to develop a tool for predicting the short-term and long-term outcomes of CAP in patients with diabetes.Methods: A retrospective study was conducted on 531 CAP patients with type 2 diabetes. The short-term outcome was in-hospital mortality. The long-term outcome was 24-month all-cause death. The APUA score was calculated according to the levels of Age (0-2 points), Pulse (0-2 points), Urea (0-2 points), and Albumin (0-4 points). The area under curves (AUCs) were used to evaluate the abilities of the APUA score for predicting short-term outcomes. Cox regression models were used for modeling relationships between the APUA score and 24-month mortality.Results: The AUC of the APUA score for predicting in-hospital mortality was 0.807 in patients with type 2 diabetes (PPPP=0.038).Conclusion: The APUA score is a simple and accurate tool for predicting short-term and long-term outcomes of CAP patients with diabetes.
- 1 June 2022
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 882977
Open AccessAge, Pulse, Urea, and Albumin Score: A Tool for Predicting the Short-Term and Long-Term Outcomes of Community-Acquired Pneumonia Patients With Diabetes
Objective: The predictive performances of CURB-65 and pneumonia severity index (PSI) were poor in patients with diabetes. This study aimed to develop a tool for predicting the short-term and long-term outcomes of CAP in patients with diabetes.Methods: A retrospective study was conducted on 531 CAP patients with type 2 diabetes. The short-term outcome was in-hospital mortality. The long-term outcome was 24-month all-cause death. The APUA score was calculated according to the levels of Age (0-2 points), Pulse (0-2 points), Urea (0-2 points), and Albumin (0-4 points). The area under curves (AUCs) were used to evaluate the abilities of the APUA score for predicting short-term outcomes. Cox regression models were used for modeling relationships between the APUA score and 24-month mortality.Results: The AUC of the APUA score for predicting in-hospital mortality was 0.807 in patients with type 2 diabetes (PPPP=0.038).Conclusion: The APUA score is a simple and accurate tool for predicting short-term and long-term outcomes of CAP patients with diabetes.
- 30 May 2022
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 35 (7) , 901-912
The relationship between metabolic syndrome and bone mineral density in adolescents: analysis of the National Health and Nutrition Examination Survey
Objectives The purpose of this study was to observe the relationship between metabolic syndrome (MetS) and height (Ht) adjusted Z-scores for areal bone mineral density (aBMD) in adolescents. Methods A retrospective study was conducted on the United States adolescents aged 12–17 years. Data were extracted from the National Health and Nutrition Examination Survey (NHANES) 2011–2012, 2013–2014 and 2015–2016 cycles. Ht adjusted Z-scores for aBMD were calculated. Results A total of 969 adolescents (493 boys and 476 girls), aged 14.5 ± 1.7 years were enrolled in this study. After control for age, gender, race, 25-hydroxyvitamin D [25(OH)D], and lean body mass index (LBMI) Z-score, adolescents with MetS had significantly lower levels of total body (less head) aBMD Ht-Z-adjusted Z-score than adolescents with one, two components of MetS and without component of MetS (pβ=−0.027, p2=0.057) and homeostasis model assessment insulin resistance (HOMA-IR) (β=−0.225, p2=0.016). There were significantly negative associations between lumbar spine aBMD Ht-Z-adjusted Z-score and WC (β=−0.039, p2=0.058) and HOMA-IR (β=−0.251, p2=0.008). Conclusion The present study demonstrates that MetS may have a negative effect on bone mineral density in adolescents. Abdominal obesity and insulin resistance play a major role on the decline of aBMD in adolescents.
- 30 May 2022
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 35 (7) , 901-912
The relationship between metabolic syndrome and bone mineral density in adolescents: analysis of the National Health and Nutrition Examination Survey
Objectives The purpose of this study was to observe the relationship between metabolic syndrome (MetS) and height (Ht) adjusted Z-scores for areal bone mineral density (aBMD) in adolescents. Methods A retrospective study was conducted on the United States adolescents aged 12–17 years. Data were extracted from the National Health and Nutrition Examination Survey (NHANES) 2011–2012, 2013–2014 and 2015–2016 cycles. Ht adjusted Z-scores for aBMD were calculated. Results A total of 969 adolescents (493 boys and 476 girls), aged 14.5 ± 1.7 years were enrolled in this study. After control for age, gender, race, 25-hydroxyvitamin D [25(OH)D], and lean body mass index (LBMI) Z-score, adolescents with MetS had significantly lower levels of total body (less head) aBMD Ht-Z-adjusted Z-score than adolescents with one, two components of MetS and without component of MetS (pβ=−0.027, p2=0.057) and homeostasis model assessment insulin resistance (HOMA-IR) (β=−0.225, p2=0.016). There were significantly negative associations between lumbar spine aBMD Ht-Z-adjusted Z-score and WC (β=−0.039, p2=0.058) and HOMA-IR (β=−0.251, p2=0.008). Conclusion The present study demonstrates that MetS may have a negative effect on bone mineral density in adolescents. Abdominal obesity and insulin resistance play a major role on the decline of aBMD in adolescents.
- Open Access
- 30 January 2022
- Published by Elsevier in Academic Radiology
- Vol. 29 (10) , e205-e210
Low Skeletal Muscle Area at the T12 Paravertebral Level as a Prognostic Marker for Community-Acquired Pneumonia
- 30 January 2022
- Published by Elsevier in Academic Radiology
- Vol. 29 (10) , e205-e210
Open AccessLow Skeletal Muscle Area at the T12 Paravertebral Level as a Prognostic Marker for Community-Acquired Pneumonia